SCOPUS 정보 검색 플랫폼

Volumn 23, Issue 6, 2000, Pages 576-579

Phase I clinical trial of a day-1, -3, -5 every 3 weeks schedule with titanocene dichloride (MKT 5) in patients with advanced cancer: A study of the phase I study group of the association for medical oncology (AIO) of the German Cancer Society

(7) Mross, K a Robben Bathe, P a Edler, L b Baumgart, J c Berdel, W E d Fiebig, H a Unger, C d

a UNIVERSITY OF FREIBURG (Germany)

b GERMAN CANCER RESEARCH CENTER DKFZ (Germany)

c MEDAC GMBH (Germany)

d UNIVERSITY HOSPITAL MÜNSTER (Germany)

Author keywords

Phase I study; Titanocene dichloride

Indexed keywords

MKT 5; TITANOCENE DICHLORIDE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; INFUSION PUMP; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; VOMITING;

EID: 0034517194 PISSN: 0378584X EISSN: None Source Type: Journal
DOI: 10.1159/000055009 Document Type: Article

Times cited : (66)

References (12)

1
- 0002499907
- Platinum analogues
- Chabner BA, Collins JM (eds): Cancer Chemotherapy. Philadelphia, Lippincott
- (1990) , pp. 465-490
- Reed, E.¹ Kohn, K.W.²

2
- 0019519118
- In vitro growth inhibition by metallocene dichlorides
- (1981) Cancer Chemother Pharmacol , vol.5 , pp. 237-241
- Köpf-Meier, P.¹ Wagner, W.² Köpf, H.³

3
- 0031779573
- Anti-proliferative activity and mechanism of action of titanocene dichloride
- (1998) Br J Cancer , vol.77 , pp. 2088-2097
- Cristodoulou, C.V.¹ Eliopoulos, A.G.² Young, L.S.³ Hodgkins, L.⁴ Ferry, D.R.⁵ Kerr, D.J.⁶

4
- 0006508335
- Titanocendichlorid: Ein neu entwickeltes, metallorganisches Zytostatikum
- München, Zuckschwerdt
- (1995) Aktuelle Onkologie , vol.84 , pp. 1-23
- Köpf-Meier, P.¹ Köpf, H.²

5
- 0031757390
- Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors
- (1998) Clin Cancer Res , vol.4 , pp. 2701-2708
- Korfel, A.¹ Scheulen, M.E.² Schmoll, H.J.³ Gründel, O.⁴ Harstrick, A.⁵ Knoche, M.⁶ Fels, L.M.⁷ Skorzec, M.⁸ Bach, F.⁹ Baumgart, J.¹⁰ Saß, G.¹¹ Seeber, S.¹² Thiel, E.¹³ Berdel, W.E.¹⁴

6
- 0031927312
- Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer
- (1998) J Clin Oncol , vol.16 , pp. 2761-2769
- Christodoulou, C.V.¹ Ferry, D.R.² Fyfe, D.W.³ Young, A.⁴ Doran, J.⁵ Sheehan, T.M.T.⁶ Eliopoulos, A.⁷ Hale, K.⁸ Baumgart, J.⁹ Sass, G.¹⁰ Kerr, D.J.¹¹

7
- 0031661569
- Phase II trial of titanocene dichloride in advanced renal-cell carcinoma
- (1998) Cancer Chemother Pharmacol , vol.42 , pp. 415-417
- Lümmen, G.¹ Sperling, H.² Luboldt, H.³ Otto, T.⁴ Rübben, H.⁵

8
- 0342948839
- Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer
- (2000) Onkologie , vol.23 , pp. 60-62
- Kröger, N.¹ Kleeberg, U.R.² Mross, K.³ Edler, L.⁴ Saß, G.⁵ Hossfeld, D.K.⁶

9
- 0028650302
- Inhibition of angiogenesis by anthracyclines and titanocene dichloride
- (1994) Ann N Y Acad Sci , vol.6 , pp. 280-293
- Maragoudakis, M.E.¹ Peristeris, P.² Missirlis, E.³ Aletras, A.⁴ Andriopoulou, P.⁵ Haralabopoulos, G.⁶

10
- 0028069274
- Suppresion of angiogenesis by the antitumor agent titanocene dichloride
- (1994) Eur J Pharmacol , vol.14 , pp. 263-269
- Bastaki, M.¹ Missirlis, E.² Klouras, N.³ Maragoudakis, M.E.⁴

11
- 0034048358
- Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
- (2000) J Clin Invest , vol.105 , pp. 1045-1047
- Hanahan, D.¹ Bergers, G.² Bergsland, E.³

12
- 0033826472
- Anti-angiogenesis therapy: Concepts and importance of dosing schedules in clinical trials
- (2000) Drug Resist Update , vol.3 , pp. 223-235
- Mross, K.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.